ArticleMedical hypothesis, discovery & innovation ophthalmology journal2024
Multifocal electroretinogram changes after panretinal photocoagulation in early proliferative diabetic retinopathy.
Article in Medical hypothesis, discovery & innovation ophthalmology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retinal Biomarkers in Diabetic Retinopathy: From Early Detection to Personalized Treatment.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Panretinal photocoagulation (PRP) impacts macular function in eyes with early proliferative diabetic retinopathy (PDR). Herein, we used the multifocal electroretinogram (mfERG) to objectively investigate this concept. Methods: In this prospective interventional case series, we enrolled patients with treatment-naive early PDR, absence of clinically significant macular edema, and requirement for PRP. All participants underwent detailed ocular examinations. We measured the best-corrected distance visual acuity (BCDVA), conducted optical coherence tomography imaging to measure central macular thickness (CMT), and performed mfERG at baseline and 3 months post-PRP. Amplitude and latency of the mfERG response were evaluated within the innermost four of the five concentric rings. Results: We enrolled 29 eyes of 23 patients with a mean (standard deviation) age of 54.3 (8.8) years and male-to-female ratio of 1:1.3. The mean BCDVA was unchanged post-treatment ( Conclusions: Macular function was decreased 3 months post-PRP in patients with early PDR, as indicated by decreased amplitude of the mfERG, whereas the functional and anatomical parameters were stable. The mfERG served as an objective tool for measuring retinal function and predicting visual outcomes post-PRP in eyes with early PDR. A higher amplitude in the mfERG correlated substantially with a better visual outcome post-PRP. Further multi-center longitudinal studies with robust designs including different PDR severity levels may reveal additional objective after-effects of PRP
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.